# Vistagen Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Vistagen Therapeutics, Inc.). ## Overview Vistagen Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on neuroscience disorders. Its pipeline centers on pherine product candidates, including intranasal therapies being developed for anxiety, depression, and other central nervous system indications. ## Products & services • Fasedienol for acute social anxiety disorder • Itruvone for major depressive disorder • PH80 for vasomotor symptoms and PMDD • PH15 for psychomotor impairment due to mental fatigue • PH284 for cancer cachexia • Sublicense and collaboration revenue - **Pherine product candidates** (95%) — Intranasal neuroscience drug candidates designed to treat anxiety, mood, and related disorders. - **Sublicense and other revenue** (5%) — Revenue recognized from collaboration, sublicense, and related contractual arrangements. - Fasedienol for acute social anxiety disorder - Itruvone for major depressive disorder - PH80 for vasomotor symptoms and PMDD - PH15 for psychomotor impairment due to mental fatigue - PH284 for cancer cachexia - Sublicense and collaboration revenue ## Customers Vistagen does not yet sell approved commercial products; its economic counterparties are primarily licensing partners, research collaborators, CROs, CDMOs, and clinical trial sites. If approved, its end customers would be patients treated by physicians in psychiatry, neurology, women’s health, and other specialty care settings. - **Licensing and collaboration partners** (primary) — Buy or license development rights and support commercialization through strategic agreements. - **CROs and CDMOs** (primary) — Provide outsourced development, testing, and manufacturing capacity that enables the pipeline. - **Clinical trial sites and investigators** (primary) — Run the studies needed to generate safety and efficacy data for regulatory approval. - **Specialty physicians and patients** (emerging) — Future end users of approved therapies for social anxiety, depression, and related disorders. - Pharmaceutical partners in sublicense and collaboration deals - CROs and CDMOs supporting clinical and manufacturing work - Clinical investigators and trial sites running studies - Physicians treating anxiety, depression, and women’s health disorders - Patients with unmet needs in neuroscience indications ## Geography Vistagen is headquartered in the United States and operates from South San Francisco, California. Its development and manufacturing network is U.S.-centered, but the company also contemplates backup manufacturing and future supply arrangements outside the U.S. for approved products. - Headquartered in South San Francisco, California - U.S. is the core base for research and clinical operations - Clinical and regulatory work is primarily U.S.-focused - Future commercial supply may use U.S. and non-U.S. CDMOs - Potential future approvals could expand exposure beyond the U.S. ## Strategy The company’s strategy is to advance its lead pherine candidates through clinical development and regulatory review, with fasedienol as the most advanced program. It also seeks partnerships and non-dilutive funding where possible while building the manufacturing and supply chain capabilities needed for eventual commercialization. - **Advance fasedienol toward approval** (short-term) — It is the lead asset and the most direct path to a first commercial product. - **Broaden the pipeline beyond fasedienol** (medium-term) — A broader portfolio reduces dependence on a single indication and expands future market opportunities. - **Secure development and commercial supply** (medium-term) — Clinical and future commercial execution depend on reliable manufacturing and backup sourcing. - Advance fasedienol through late-stage development and FDA review - Progress PH80 and other pipeline assets into clinical testing - Use partnerships and non-dilutive capital to extend runway - Prepare commercial supply through CDMO and backup sourcing plans - Protect intellectual property around pherine technologies ## Risks Vistagen is exposed to the typical risks of clinical-stage drug development: trial failure, regulatory delay, manufacturing complexity, and competition from larger pharmaceutical companies. Because it has not yet commercialized a product, its business depends heavily on successful clinical outcomes, access to capital, and protection of its intellectual property. - **Clinical development failure** [critical] — Product candidates may not demonstrate sufficient efficacy or tolerability in trials. - **Regulatory approval risk** [high] — FDA or other regulators may require additional data or reject applications. - **Funding risk** [high] — The company expects existing resources to be insufficient beyond the near term. - **Competitive intensity** [high] — Large pharma and biotech firms have greater resources and established commercial reach. - **Manufacturing and supply chain execution** [medium] — Commercial supply depends on CDMOs and future backup manufacturing arrangements. - Clinical trials may fail to meet endpoints or show safety issues - Regulatory review can delay or block approval of product candidates - The company depends on external funding to support development - Competition from larger drug makers may limit market opportunity - Manufacturing and supply chain gaps could affect future launch readiness ## Accounting The most important accounting judgments are in research and development expense accruals, because the company relies on CROs, CDMOs, and clinical sites whose invoices may lag performance. Revenue is limited and tied to sublicense/collaboration arrangements, so timing of milestone or performance-obligation recognition can affect reported periods. Lease accounting and estimates around prepaid expenses, accrued liabilities, and potential future manufacturing commitments also matter for interpreting cash needs and operating leverage. - **Research and development accruals** — Can shift expenses between periods and affect reported operating loss - **Sublicense and other revenue recognition** — Can create uneven quarterly revenue recognition - **Lease accounting** — Affects right-of-use assets, lease liabilities, and fixed commitments - **Future manufacturing and purchase obligations** — Could increase future liabilities and cash requirements - R&D costs are expensed as incurred, affecting reported losses - Accruals for CRO/CDMO work depend on estimates of service progress - Sublicense revenue timing depends on performance obligations - Operating lease commitments affect balance sheet and cash planning - Future manufacturing commitments may create purchase obligations --- *Last updated: 2026-04-29T05:08:23.719180+00:00*